Beatriz Haddad Maia fails drug test: Tennis career in jeopardy

by   |  VIEW 12314

Beatriz Haddad Maia fails drug test: Tennis career in jeopardy

The last time that the Brazilian qualifier Beatriz Haddad Maia made headlines was when she played opposite No. 26 seed Garbine Muguruza at the opening of this year's Wimbledon Championships. She caused an upset of the 2017 former champion in an one hour and 30 minutes 6-4, 6-4 victory.

This was the first time that Muguruza had ever lost an opening-round at a major in 5 years. The 23-year-old Brazilian was overjoyed to have qualified for Wimbledon's main draw in July since last year she had a serious back injury requiring surgery.

As a result she missed last year's French Open and Wimbledon but glad to be able to play these tournaments this year. It was on June 4th the No. 99 ranked was required to provide a random urine sample during the Croatia Open and was found to contain SARM S-22 and SARM LGD-4033 metabolite.

These are banned anabolic agents that are considered selective androgen receptor modulators. Synthetic in nature these drugs have similar effects as anabolic steroids popular with weightlifters and other athletes. SARMs are prohibited by the World Anti-Doping Agency.

Haddad Maia was told of the findings on July 12 after she had defeated Garbine Muguruza in the opening round and was defeated by Harriet Dart in the second round. She was given a provisional suspension by the International Tennis Federation (ITF) that became effective on Monday, July 22.

The Brazilian player has been given time to apply to the chair of the Independent Tribune as to why the provisional suspension should not be imposed. But the ITF or the World Anti-Doping Agency hasn't heard back from the Brazilian player as of yet.

No length of time has been imposed yet as for how long she'll be provisionally suspended. As of now Beatriz Haddad Maia is prohibited from competing in, attending any sanctioned event organized or recognized by the sport of tennis.